

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6258662

|   |                                   |
|---|-----------------------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                    |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                        |
| <b>CONVEYING PARTY DATA</b>   |                                   |
| <b>Name</b>   | <b>Execution Date</b>             |
| TAKASHI OKADA   | 04/26/2020                        |
| TSUTOMU IGARASHI  | 04/25/2020                        |
| ASAKA SHIOZAWA  | 04/27/2020                        |
| <b>RECEIVING PARTY DATA</b>   |                                   |
| <b>Name:</b>  | NIPPON MEDICAL SCHOOL FOUNDATION  |
| <b>Street Address:</b>  | 1-1-5 SENDAGI, BUNKYO-KU          |
| <b>City:</b>  | TOKYO                             |
| <b>State/Country:</b>   | JAPAN                             |
| <b>Postal Code:</b>   | 1138602                           |
| <b>Name:</b>  | TEIKA PHARMACEUTICAL CO., LTD.    |
| <b>Street Address:</b>  | 3-27, ARAKAWA 1-CHOME, TOYAMA-SHI |
| <b>City:</b>  | TOYAMA                            |
| <b>State/Country:</b>   | JAPAN                             |
| <b>Postal Code:</b>   | 9300982                           |
| <b>PROPERTY NUMBERS Total: 1</b>  |                                   |
| <b>Property Type</b>  | <b>Number</b>                     |
| Application Number:   | 16968397                          |
| <b>CORRESPONDENCE DATA</b>  |                                   |
| <b>Fax Number:</b>  | (617)428-7045                     |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                                   |
| <b>Phone:</b>   | (617) 428-0200                    |
| <b>Email:</b>   | patentadmin@clarkelbing.com       |
| <b>Correspondent Name:</b>  | CLARK & ELBING LLP                |
| <b>Address Line 1:</b>  | 101 FEDERAL STREET                |
| <b>Address Line 2:</b>  | 15TH FLOOR                        |
| <b>Address Line 4:</b>  | BOSTON, MASSACHUSETTS 02110       |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 51007-019001                      |
| <b>NAME OF SUBMITTER:</b>   | SUSAN M. MICHAUD, PH.D.           |

|   |  |
|---|--|
| <b>SIGNATURE:</b>   | /Susan M. Michaud, Ph.D./                                  |
| <b>DATE SIGNED:</b>   | 08/19/2020   |
|   | This document serves as an Oath/Declaration (37 CFR 1.63). |
| <b>Total Attachments: 3</b><br>source=Executed Combined Declarations and Assignment#page1.tif<br>source=Executed Combined Declarations and Assignment#page2.tif<br>source=Executed Combined Declarations and Assignment#page3.tif |  |

**DECLARATION (37 CFR 1.63) FOR UTILITY APPLICATION USING AN APPLICATION  
DATA SHEET (37 CFR 1.76) AND ASSIGNMENT**

As a below named inventor, I hereby declare that:

This declaration is directed to United States or PCT international application number PCT/JP2019/001090, filed on January 16, 2019, and entitled "Improved Adeno-Associated Virus Vector."

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

For valuable consideration, I hereby assign to Nippon Medical School Foundation, having a place of business at 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 1138602, Japan, and to Teika Pharmaceutical Co., Ltd., having a place of business at 3-27, Arakawa 1-chome, Toyama-shi, Toyama 9300982, Japan and to their respective successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are the subject of said application.

This assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and I agree for myself and my respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

Inventor: Takashi OKADA

Date: April 26, 2020

Signature: Takashi Okada

Inventor: Tsutomu IGARASHI

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Inventor: Asaka SHIOZAWA

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

**DECLARATION (37 CFR 1.63) FOR UTILITY APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) AND ASSIGNMENT**

As a below named inventor, I hereby declare that:

This declaration is directed to United States or PCT international application number PCT/JP2019/001090, filed on January 16, 2019, and entitled "Improved Adeno-Associated Virus Vector."

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

For valuable consideration, I hereby assign to Nippon Medical School Foundation, having a place of business at 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 1138602, Japan, and to Teika Pharmaceutical Co., Ltd., having a place of business at 3-27, Arakawa 1-chome, Toyama-shi, Toyama 9300982, Japan and to their respective successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are the subject of said application.

This assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and I agree for myself and my respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

Inventor: Takashi OKADA

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Inventor: Tsutomu IGARASHI

Date: 4/25/2020

Signature: T. Igarashi

Inventor: Asaka SHIOZAWA

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

**DECLARATION (37 CFR 1.63) FOR UTILITY APPLICATION USING AN APPLICATION  
DATA SHEET (37 CFR 1.76) AND ASSIGNMENT**

As a below named inventor, I hereby declare that:

This declaration is directed to United States or PCT international application number PCT/JP2019/001090, filed on January 16, 2019, and entitled "Improved Adeno-Associated Virus Vector."

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

For valuable consideration, I hereby assign to Nippon Medical School Foundation, having a place of business at 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 1138602, Japan, and to Teika Pharmaceutical Co., Ltd., having a place of business at 3-27, Arakawa 1-chome, Toyama-shi, Toyama 9300982, Japan and to their respective successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are the subject of said application.

This assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and I agree for myself and my respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

Inventor: Takashi OKADA

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Inventor: Tsutomu IGARASHI

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Inventor: Asaka SHIOZAWA

Date: April 27, 2020

Signature: Asaka Shiozawa